EULAV Asset Management trimmed its position in Exact Sciences Co. (NASDAQ:EXAS - Free Report) by 6.6% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 285,000 shares of the medical research company's stock after selling 20,000 shares during the quarter. EULAV Asset Management owned approximately 0.15% of Exact Sciences worth $16,014,000 at the end of the most recent quarter.
Other institutional investors have also made changes to their positions in the company. Geode Capital Management LLC increased its holdings in shares of Exact Sciences by 0.3% in the 3rd quarter. Geode Capital Management LLC now owns 3,105,970 shares of the medical research company's stock valued at $211,104,000 after purchasing an additional 7,873 shares during the period. Champlain Investment Partners LLC increased its stake in Exact Sciences by 10.9% in the 3rd quarter. Champlain Investment Partners LLC now owns 2,494,480 shares of the medical research company's stock valued at $169,924,000 after buying an additional 245,980 shares during the period. Bellevue Group AG lifted its position in Exact Sciences by 25.1% in the 3rd quarter. Bellevue Group AG now owns 1,449,465 shares of the medical research company's stock worth $98,738,000 after buying an additional 290,585 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its position in Exact Sciences by 3.6% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,292,090 shares of the medical research company's stock worth $88,017,000 after buying an additional 45,015 shares in the last quarter. Finally, Groupama Asset Managment acquired a new stake in shares of Exact Sciences during the 3rd quarter valued at $821,000. 88.82% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analysts Forecast Growth
A number of equities analysts have recently weighed in on the stock. Benchmark reaffirmed a "buy" rating and issued a $65.00 price target on shares of Exact Sciences in a research note on Monday, January 13th. Craig Hallum dropped their target price on Exact Sciences from $82.00 to $65.00 and set a "buy" rating on the stock in a research report on Wednesday, November 6th. TD Cowen lifted their price target on Exact Sciences from $82.00 to $86.00 and gave the company a "buy" rating in a report on Tuesday, November 26th. Jefferies Financial Group boosted their price target on Exact Sciences from $84.00 to $85.00 and gave the company a "buy" rating in a research note on Wednesday, November 6th. Finally, Bank of America cut their price objective on shares of Exact Sciences from $75.00 to $72.00 and set a "buy" rating on the stock in a research report on Friday, December 13th. One investment analyst has rated the stock with a hold rating and eighteen have given a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $72.76.
Check Out Our Latest Research Report on EXAS
Exact Sciences Price Performance
Shares of Exact Sciences stock traded down $0.72 during midday trading on Wednesday, hitting $50.34. 1,426,910 shares of the company were exchanged, compared to its average volume of 2,150,925. The firm has a 50 day simple moving average of $56.66 and a 200-day simple moving average of $60.13. Exact Sciences Co. has a 52 week low of $40.62 and a 52 week high of $79.62. The firm has a market cap of $9.32 billion, a P/E ratio of -43.03 and a beta of 1.24. The company has a debt-to-equity ratio of 0.72, a current ratio of 2.12 and a quick ratio of 1.93.
Exact Sciences Company Profile
(
Free Report)
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.
Further Reading
Before you consider Exact Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Exact Sciences wasn't on the list.
While Exact Sciences currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
